Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Octagam 5% pharmacokinetic, efficacy and safety study in adults with primary immunodeficiency diseases
ISRCTN32382999Phase 3Completed
- Sponsor
- Octapharma
- Start
- Jul 2012
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 3, open-label trial of Human normal immunoglobulin G in Immunogenetic disorder (2 arms), sponsored by Octapharma. Primary endpoint: Pharmacokinetic profile of Octagam 5%. Started Jul 2012; status: completed.
02
Drugs
Human normal immunoglobulin G
03
Conditions
Immunogenetic disorder
Beyond the preview
Go deeper on ISRCTN32382999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN32382999.